ID   OCI-Ly3
AC   CVCL_8800
SY   OCI-LY3; OCI-ly3; OCI-LY-3; Oci-Ly-3; OCI-Ly 3; OCILY-3; OCI-Ly03; OCI Ly3; OCILY3; Ly3; LY3
DR   EFO; EFO_0006710
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioGRID_ORCS_Cell_line; 745
DR   BioSample; SAMN10988130
DR   cancercelllines; CVCL_8800
DR   Cell_Model_Passport; SIDM01778
DR   ChEMBL-Cells; CHEMBL4523534
DR   ChEMBL-Targets; CHEMBL4523565
DR   Cosmic; 1290019
DR   Cosmic; 1329094
DR   Cosmic; 1486584
DR   Cosmic; 1487544
DR   Cosmic; 1517647
DR   Cosmic; 1541901
DR   Cosmic; 1548654
DR   Cosmic; 1550337
DR   Cosmic; 1945198
DR   Cosmic; 2276329
DR   Cosmic; 2437309
DR   DepMap; ACH-000158
DR   DSMZ; ACC-761
DR   DSMZCellDive; ACC-761
DR   EGA; EGAS00001000610
DR   ENCODE; ENCBS018GXW
DR   ENCODE; ENCBS757GPD
DR   GEO; GSM2023
DR   GEO; GSM1963
DR   GEO; GSM380133
DR   GEO; GSM552451
DR   GEO; GSM887472
DR   GEO; GSM888552
DR   GEO; GSM1035342
DR   GEO; GSM1059799
DR   GEO; GSM1374787
DR   GEO; GSM1890025
DR   GEO; GSM1890026
DR   GEO; GSM1890027
DR   GEO; GSM1890028
DR   GEO; GSM3150251
DR   IARC_TP53; 26922
DR   LiGeA; CCLE_060
DR   Lonza; 945
DR   PharmacoDB; OCILY3_1189_2019
DR   PRIDE; PXD012087
DR   Progenetix; CVCL_8800
DR   PubChem_Cell_line; CVCL_8800
DR   Wikidata; Q54931773
RX   PubMed=3567358;
RX   PubMed=8574164;
RX   PubMed=10676951;
RX   PubMed=11807979;
RX   PubMed=15122589;
RX   PubMed=18323416;
RX   PubMed=19278952;
RX   PubMed=20054396;
RX   PubMed=20628145;
RX   PubMed=20889926;
RX   PubMed=21179087;
RX   PubMed=22460905;
RX   PubMed=23257783;
RX   PubMed=23292937;
RX   PubMed=23699601;
RX   PubMed=23321251;
RX   PubMed=25485619;
RX   PubMed=26589293;
RX   PubMed=28196595;
RX   PubMed=29416618;
RX   PubMed=29666304;
RX   PubMed=30285677;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=31978347;
WW   http://www.innovationbridge.com/uhn/diffuse-large-b-cell-lymphoma-cell-lines?categories=32&communities=5&forums=&organizations=&tags=
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   From: Ontario Cancer Institute (OCI); Toronto; Canada.
CC   Population: Caucasian.
CC   Doubling time: ~24 hours (DSMZ=ACC-761).
CC   HLA typing: A*01:01,03:01; B*08:01,08:01; C*07:01,07:01 (PubMed=26589293).
CC   HLA typing: A*01:01:01,03:01:01; B*08:01:01,08:01:01; C*07:01:01,07:01:01; DPA1*02:01:02,02:01:02; DPB1*01:01:01,01:01:01; DQA1*05:01:01,05:01:01; DQB1*02:01:01,02:01:01; DRA*01:02:02,01:02:02; DRB1*03:01:01,03:01:01 (DSMZCellDive=ACC-761).
CC   Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 11242; SPIB; Name(s)=IGH-SPIB (PubMed=31160637; DSMZ=ACC-761).
CC   Sequence variation: Mutation; HGNC; 16393; CARD11; Simple; p.Leu251Pro (c.752T>C) (L244P); ClinVar=VCV001017661; Zygosity=Homozygous (PubMed=18323416; DepMap).
CC   Sequence variation: Mutation; HGNC; 7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Homozygous (PubMed=21179087; PubMed=23321251; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Genome sequenced.
CC   Omics: H3K9ac ChIP-seq epigenome analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.02%; Native American=0%; East Asian, North=4.08%; East Asian, South=0%; South Asian=0%; European, North=65.42%; European, South=30.48% (PubMed=30894373).
CC   Caution: A cell line, now termed GNE-587170 (Cellosaurus=CVCL_AT69), was mistakenly distributed by OCI to a number of groups under the designation OCI-Ly-3, the origin of that cell line is now known.
CC   Misspelling: Ocl-Ly3; GEO=GSM3150251.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 17
ST   D19S433: 13,15
ST   D21S11: 28
ST   D2S1338: 24
ST   D3S1358: 14
ST   D5S818: 12
ST   D7S820: 11,12
ST   D8S1179: 12,13
ST   FGA: 21,23
ST   Penta D: 9
ST   Penta E: 7,11
ST   TH01: 7,9.3
ST   TPOX: 8,12
ST   vWA: 17
DI   NCIt; C36081; Diffuse large B-cell lymphoma activated B-cell type
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   52Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 30-01-24; Version: 37
//
RX   PubMed=3567358; DOI=10.1182/blood.V69.5.1307.1307;
RA   Tweeddale M.E., Lim B., Jamal N., Robinson J., Zalcberg J.R.,
RA   Lockwood G., Minden M.D., Messner H.A.;
RT   "The presence of clonogenic cells in high-grade malignant lymphoma: a
RT   prognostic factor.";
RL   Blood 69:1307-1314(1987).
//
RX   PubMed=8574164; DOI=10.3109/10428199509059672;
RA   Chang H., Blondal J.A., Benchimol S., Minden M.D., Messner H.A.;
RT   "p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's
RT   lymphoma cell lines.";
RL   Leuk. Lymphoma 19:165-171(1995).
//
RX   PubMed=10676951; DOI=10.1038/35000501;
RA   Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S.,
RA   Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., Powell J.I.,
RA   Yang L.-M., Marti G.E., Moore T., Hudson J. Jr., Lu L.-S., Lewis D.B.,
RA   Tibshirani R., Sherlock G., Chan W.C., Greiner T.C.,
RA   Weisenburger D.D., Armitage J.O., Warnke R.A., Levy R., Wilson W.,
RA   Grever M.R., Byrd J.C., Botstein D., Brown P.O., Staudt L.M.;
RT   "Distinct types of diffuse large B-cell lymphoma identified by gene
RT   expression profiling.";
RL   Nature 403:503-511(2000).
//
RX   PubMed=11807979; DOI=10.1002/gcc.10025;
RA   Mehra S., Messner H.A., Minden M.D., Chaganti R.S.K.;
RT   "Molecular cytogenetic characterization of non-Hodgkin lymphoma cell
RT   lines.";
RL   Genes Chromosomes Cancer 33:225-234(2002).
//
RX   PubMed=15122589; DOI=10.1002/ijc.20170;
RA   Liggins A.P., Guinn B.A., Hatton C.S., Pulford K., Banham A.H.;
RT   "Serologic detection of diffuse large B-cell lymphoma-associated
RT   antigens.";
RL   Int. J. Cancer 110:563-569(2004).
//
RX   PubMed=18323416; DOI=10.1126/science.1153629;
RA   Lenz G., Davis R.E., Ngo V.N., Lam L., George T.C., Wright G.W.,
RA   Dave S.S., Zhao H., Xu W.-H., Rosenwald A., Ott G.,
RA   Muller-Hermelink H.-K., Gascoyne R.D., Connors J.M., Rimsza L.M.,
RA   Campo E., Jaffe E.S., Delabie J., Smeland E.B., Fisher R.I.,
RA   Chan W.C., Staudt L.M.;
RT   "Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.";
RL   Science 319:1676-1679(2008).
//
RX   PubMed=19278952; DOI=10.1182/blood-2009-01-202028;
RA   Li C., Kim S.-W., Rai D., Bolla A.R., Adhvaryu S., Kinney M.C.,
RA   Robetorye R.S., Aguiar R.C.T.;
RT   "Copy number abnormalities, MYC activity, and the genetic fingerprint
RT   of normal B cells mechanistically define the microRNA profile of
RT   diffuse large B-cell lymphoma.";
RL   Blood 113:6681-6690(2009).
//
RX   PubMed=20054396; DOI=10.1038/nature08638;
RA   Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B.,
RA   Kohlhammer H., Lamy L., Zhao H., Yang Y.-D., Xu W.-H., Shaffer A.L. III,
RA   Wright G., Xiao W.-M., Powell J.I., Jiang J.-K., Thomas C.J., Rosenwald A.,
RA   Ott G., Muller-Hermelink H.-K., Gascoyne R.D., Connors J.M.,
RA   Johnson N.A., Rimsza L.M., Campo E., Jaffe E.S., Wilson W.H.,
RA   Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R.,
RA   Cook J.R., Weisenburger D.D., Chan W.C., Pierce S.K., Staudt L.M.;
RT   "Chronic active B-cell-receptor signalling in diffuse large B-cell
RT   lymphoma.";
RL   Nature 463:88-92(2010).
//
RX   PubMed=20628145; DOI=10.1182/blood-2010-05-282780;
RA   Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T.,
RA   O'Donnell E., Chapuy B., Takeyama K., Neuberg D., Golub T.R.,
RA   Kutok J.L., Shipp M.A.;
RT   "Integrative analysis reveals selective 9p24.1 amplification,
RT   increased PD-1 ligand expression, and further induction via JAK2 in
RT   nodular sclerosing Hodgkin lymphoma and primary mediastinal large
RT   B-cell lymphoma.";
RL   Blood 116:3268-3277(2010).
//
RX   PubMed=20889926; DOI=10.1182/blood-2010-06-290437;
RA   Pham L.V., Fu L.-C., Tamayo A.T., Bueso-Ramos C.E., Drakos E.,
RA   Vega-Vazquez F., Medeiros L.J., Ford R.J. Jr.;
RT   "Constitutive BR3 receptor signaling in diffuse, large B-cell
RT   lymphomas stabilizes nuclear factor-kappaB-inducing kinase while
RT   activating both canonical and alternative nuclear factor-kappaB
RT   pathways.";
RL   Blood 117:200-210(2011).
//
RX   PubMed=21179087; DOI=10.1038/nature09671;
RA   Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W.-M., Lim K.-H.,
RA   Kohlhammer H., Xu W.-H., Yang Y.-D., Zhao H., Shaffer A.L. III, Romesser P.,
RA   Wright G., Powell J.I., Rosenwald A., Muller-Hermelink H.-K., Ott G.,
RA   Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S.,
RA   Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R.,
RA   Cook J.R., Weisenburger D.D., Chan W.C., Staudt L.M.;
RT   "Oncogenically active MYD88 mutations in human lymphoma.";
RL   Nature 470:115-119(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23257783; DOI=10.1038/leu.2012.367;
RA   Wenzel S.-S., Grau M., Mavis C., Hailfinger S., Wolf A., Madle H.,
RA   Deeb G., Dorken B., Thome M., Lenz P., Dirnhofer S.,
RA   Hernandez-Ilizaliturri F.J., Tzankov A., Lenz G.;
RT   "MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.";
RL   Leukemia 27:1381-1390(2013).
//
RX   PubMed=23292937; DOI=10.1073/pnas.1205299110;
RA   Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L.,
RA   Mieczkowski P.A., Dunphy C., Choi W., Au W.Y., Srivastava G.,
RA   Lugar P.L., Rizzieri D.A., Lagoo A.S., Bernal-Mizrachi L., Mann K.P.,
RA   Flowers C.R., Naresh K., Evens A.M., Gordon L.I., Czader M.B., Gill J.I.,
RA   Hsi E.D., Liu Q.-Q., Fan A., Walsh K., Jima D., Smith L.L., Johnson A.J.,
RA   Byrd J.C., Luftig M.A., Ni T., Zhu J., Chadburn A., Levy S.,
RA   Dunson D.B., Dave S.S.;
RT   "Genetic heterogeneity of diffuse large B-cell lymphoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013).
//
RX   PubMed=23699601; DOI=10.1182/blood-2013-02-483727;
RA   Morin R.D., Mungall K., Pleasance E.D., Mungall A.J., Goya R.,
RA   Huff R.D., Scott D.W., Ding J.-R., Roth A., Chiu R., Corbett R.D.,
RA   Chan F.C., Mendez-Lago M., Trinh D.L., Bolger-Munro M., Taylor G.,
RA   Hadj Khodabakhshi A., Ben-Neriah S., Pon J., Meissner B., Woolcock B.,
RA   Farnoud N., Rogic S., Lim E.L., Johnson N.A., Shah S., Jones S.J.M.,
RA   Steidl C., Holt R.A., Birol I., Moore R., Connors J.M., Gascoyne R.D.,
RA   Marra M.A.;
RT   "Mutational and structural analysis of diffuse large B-cell lymphoma
RT   using whole-genome sequencing.";
RL   Blood 122:1256-1265(2013).
//
RX   PubMed=23321251; DOI=10.1182/blood-2012-09-454355;
RA   Xu L., Hunter Z.R., Yang G., Zhou Y.-S., Cao Y., Liu X., Morra E.,
RA   Trojani A., Greco A., Arcaini L., Varettoni M., Brown J.R., Tai Y.-T.,
RA   Anderson K.C., Munshi N.C., Patterson C.J., Manning R.J.,
RA   Tripsas C.K., Lindeman N.I., Treon S.P.;
RT   "MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M
RT   monoclonal gammopathy, and other B-cell lymphoproliferative disorders
RT   using conventional and quantitative allele-specific polymerase chain
RT   reaction.";
RL   Blood 121:2051-2058(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29416618; DOI=10.18632/oncotarget.20378;
RA   Liu W., Chen J., Tamayo A.T., Ruan C.-G., Li L., Zhou S.-H., Shen C.,
RA   Young K.H., Westin J., Davis R.E., Hu S.-M., Medeiros L.J., Ford R.J. Jr.,
RA   Pham L.V.;
RT   "Preclinical efficacy and biological effects of the oral proteasome
RT   inhibitor ixazomib in diffuse large B-cell lymphoma.";
RL   Oncotarget 9:346-360(2018).
//
RX   PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004;
RA   Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H.,
RA   Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H.,
RA   Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.;
RT   "Strategic therapeutic targeting to overcome venetoclax resistance in
RT   aggressive B-cell lymphomas.";
RL   Clin. Cancer Res. 24:3967-3980(2018).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//